Tesamorelin in Minnesota: Egrifta Approval and Compounding Explained
Which tesamorelin product is approved?
FDA's Purple Book lists Egrifta SV and Egrifta WR under tesamorelin's licensed biological product application. The original approval dates to 2010. The current products have distinct presentations, so their instructions should not be treated as interchangeable. [1]
The Egrifta WR label specifies reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly says the product is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. [2]
That is a narrower statement than “tesamorelin is approved for belly fat.” Removing the HIV-associated condition changes the meaning of the approval.
Why this does not validate compounded tesamorelin
Approval concerns a particular product and application. It does not transfer to any vial containing an ingredient with the same name.
There is an additional distinction here: FDA explains that biological products are not eligible for the exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Its guidance addresses specified mixing, dilution, and repackaging circumstances, which should not be confused with ordinary bulk compounding of a substitute biological product. [3]
An article that places Egrifta and a compounded tesamorelin offer in one list of equivalent purchasing options therefore obscures an important product difference.
What Minnesota licensing can establish
The Minnesota Board of Pharmacy provides information about licensed pharmacies and applicable state practice requirements. A license check helps establish whether a pharmacy holds the relevant state authorization. It does not show that every product in an advertisement is FDA-approved or that a proposed compounding activity meets federal requirements. [4]
The same separation applies to a clinician's license. Professional authority to practice is different from the status of a particular preparation.
| Question | Relevant evidence |
|---|---|
| Is this an approved tesamorelin product? | Exact product name and FDA application record |
| What use does its label cover? | Current product-specific prescribing information |
| Is the pharmacy licensed in Minnesota? | State licensing record |
| Is a compounded offer equivalent to Egrifta? | Product-specific evidence and regulatory basis, not ingredient naming alone |
How to read an access or cost comparison
Start with the exact product. Package presentation, coverage rules, indication, and pharmacy arrangements can all affect the cost of an approved prescription. A price for a differently prepared vial is not an equivalent quote.
Likewise, a study of Egrifta cannot automatically establish the effectiveness, stability, or safety of an unrelated preparation. If an article does not identify the studied product, the reader cannot reliably connect the claim to the offer.
Frequently asked questions
Is tesamorelin completely unapproved in the United States?
No. Egrifta products are approved. The precise distinction is between those licensed products and other preparations or broader claims about use.
Is Egrifta an approved general weight-loss drug?
No. Its labeled indication concerns excess abdominal fat in adults with HIV-associated lipodystrophy, not general weight-loss management.
References
- FDA Purple Book: Tesamorelin Product Details.
- FDA: Egrifta WR Prescribing Information, 2025.
- FDA: Mixing, Diluting, or Repackaging Biological Products.
- Minnesota Board of Pharmacy.
